Royalty Pharma Raises 2026 Portfolio Receipts Guidance to $3.50-$3.55B on 9% Q3 Growth
RPRX sits 84% above its 52-week low of $36.027.
Summary
Royalty Pharma raised full-year 2026 Portfolio Receipts guidance to $3,500-$3,550 million after 9% third-quarter growth, while booking a $150 million non-cash impairment on pelacarsen.
Key Events · Earnings and Guidance · RPRX
-
Guidance Raised for Full Year 2026
Portfolio Receipts guidance lifted to $3,500-$3,550 million from $3,400-$3,500 million, implying 10%-11% Royalty Receipts growth.
-
Q3 Portfolio Receipts Up 9%
Portfolio Receipts rose to $890 million from $814 million, with Royalty Receipts of $883 million driven by Tremfya, Voranigo, Evrysdi and Imdelltra.
-
$150 Million Pelacarsen Impairment
A non-cash impairment was recorded after Novartis's Phase 3 Lp(a)HORIZON trial of pelacarsen missed its primary endpoint; GAAP net income fell to $145 million from $284 million.
-
Cash Generation and Capital Returns
Net cash from operations was $686 million and Portfolio Cash Flow $673 million; the company paid $135 million in dividends and repurchased about 1.5 million shares for $87 million in the quarter.
Analysis · RPRX · Life Sciences
Royalty Pharma beat its own trajectory and lifted full-year Portfolio Receipts guidance to $3,500-$3,550 million from $3,400-$3,500 million, with Q3 Portfolio Receipts up 9% to $890 million and Royalty Receipts up 9% to $883 million. The quarter was not clean: a $150 million non-cash impairment on pelacarsen followed Novartis's Phase 3 Lp(a)HORIZON miss, and GAAP net income fell to $145 million from $284 million a year earlier on that charge and higher operating costs. Cash generation remains the core of the story, with $686 million from operations and $673 million of Portfolio Cash Flow funding the dividend and buybacks. The raised guidance excludes any contribution from future transactions, so the $1.9 billion of announced deals this year is upside not yet in the numbers.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RPRX was trading at $66.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.3B. The 52-week trading range was $36.03 to $67.71. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.